AIM ImmunoTech Combination Therapy Well Tolerated in Late-Stage Pancreatic Cancer

AIM ImmunoTech’s (NYSE American: AIM) combination therapy for the treatment of late-stage pancreatic cancer has demonstrated safety and tolerability in a Phase 1b/2 study being conducted by the company in the Netherlands. No treatment-related severe adverse events or dose-limiting toxicities were noted by investigators at the Erasmus Medical Center, which is collaborating with AIM on the study.

AIM stated that the safety data was an essential step forward in testing the combination of its Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in pancreatic cancer patients.

Based on the results, AIM expects to escalate to the next dose and will begin dosing the next cohort of patients imminently. Subjects enrolled in the study will continue treatment for 48 weeks.

AIM’s market cap stands at $20.51 million and the company has generated a growing body of promising data demonstrating its lead candidate, Ampligen’s potential to address multiple high-value indications.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

 

Share This Article

 

About the Author

AIM ImmunoTech Combination Therapy Well Tolerated in Late-Stage Pancreatic Cancer

Catie Corcoran

Biotech Editor